跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN13643081
ISRCTN13643081已完成未知

The GRAVITAS trial: GLP­1 Receptor Agonist interVentIon for poor responders afTer bariAtric Surgery

Imperial College London0 个研究点目标入组 80 人开始时间: 2016年1月20日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
已完成
入组人数
80
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31174993 (added 10/06/2019)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1. Aged between 18­ and 70 years
  • •2. 12 months after gastric bypass or sleeve gastrectomy bariatric surgery
  • •3. Diagnosed with Type 2 diabetes mellitus
  • •4. HbA1c greater than 6.5% (more than 48 mmol/mol) on screening
  • •5. On Metformin ± long acting insulin
  • •6. Able to give informed consent

排除标准

  • •1. Diagnosis of Type 1 diabetes mellitus
  • •2. Anatomical or endocrinological pathology causing poor weight loss or weight regain
  • •3. Screening calcitonin of 50 ng/L or above
  • •4. Family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
  • •5. Personal history of non­familial medullary thyroid carcinoma
  • •6. History of acute or chronic pancreatitis
  • •7. Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100
  • •mmHg or above)
  • •8. Estimated glomerular filtration rate (eGFR) less than30 ml/min per 1.73 m2
  • •9. Current pregnancy
  • •10. Inability to maintain adequate contraception

研究者

相似试验

进行中（未招募）
2 期
Evaluating the effects of the novel GLP1 analogue, Liraglutide, in patients with Alzheimer's Disease (ELAD study)Topic: Dementias and Neurodegenerative Diseases Research NetworkSubtopic: DementiaDisease: Alzheimer's DiseaseMental and Behavioural DisordersDementia in Alzheimer disease
ISRCTN89711766Imperial College of Science, Technology and Medicine (UK)206
已完成
4 期
SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesType 2 Diabetes
NCT01744236Amsterdam UMC, location VUmc70
已完成
2 期
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?Alcohol AbuseAlcohol AddictionAlcohol Use DisorderAlcohol Dependence
NCT05895643Psychiatric Centre Rigshospitalet108
Unknown
2 期
Evaluating Liraglutide in Alzheimer's DiseaseAlzheimer's Disease
NCT01843075Imperial College London204
已完成
2 期
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?Alcohol Dependence, in RemissionAddiction, Alcohol
NCT03232112Anders Fink-Jensen, MD, DMSci152